myChoice CDx

FDA Premarket Approval P190014 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

"approval for myriad mychoice® cdx to include a companion diagnostic indication for homologous recombination deficiency (hrd) in ovarian cancer patients who may benefit from maintenance treatment with lynparza® (olaparib)"

DevicemyChoice CDx
Generic NameNext Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
ApplicantMyriad Genetic Laboratories, Inc
Date Received2020-02-11
Decision Date2020-05-08
PMAP190014
SupplementS003
Product CodePQP 
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address Myriad Genetic Laboratories, Inc 320 Wankara Way salt Lake City, UT 84108

Supplemental Filings

Supplement NumberDateSupplement Type
P190014Original Filing
S003 2020-02-11 Normal 180 Day Track
S002 2020-02-05 Real-time Process
S001 2020-01-23 Normal 180 Day Track

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.